Q-omics provides the consensus-scored RNF223 profile across patient tissues and cancer cell-line models. RNF223 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF223 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RNF223 RNA expression shows 11,181 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRC, and PAAD as cancer lineages where RNF223 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF223 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF223 survival associations across molecular data types. RNF223 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF223 RNA expression–survival associations across cancer types. High RNF223 expression shows unfavorable associations in KIRC, THCA and PAAD, but favorable associations in UCEC, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF223 RNA expression.
This table summarizes RNF223 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF223. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF223 shows lower tumor expression in KIRC, HNSC, KICH and KIRP and higher tumor expression in THCA and LUAD. The KIRC box plot shows higher RNF223 RNA expression in normal versus tumor tissue (log2 FC = −0.958, t-test p < 0.001).
This table shows molecular features associated with RNF223 in patient tissues and cancer cell lines. In patient samples, RNF223 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF223 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
